Ani Pharmaceuticals (ANIP) Cash from Investing Activities Growth (1y) (2011 - 2026)
Ani Pharmaceuticals (ANIP) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 13.93% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 57.14% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -186.78% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 551.55% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 526.11% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -3,664.79% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -3.45% |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn | 42.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.94% |
| Dec 31, 2025 | 86.86% |
| Sep 30, 2025 | 98.45% |
| Jun 30, 2025 | -55.29% |
| Mar 31, 2025 | -322.17% |
| Dec 31, 2024 | -123.50% |
| Sep 30, 2024 | -8,652.95% |
| Jun 30, 2024 | 34.82% |
| Mar 31, 2024 | 479.64% |
| Dec 31, 2023 | -52.10% |
| Sep 30, 2023 | 53.61% |
| Jun 30, 2023 | -1,030.13% |
| Mar 31, 2023 | -8.03% |
| Dec 31, 2022 | 96.18% |
| Sep 30, 2022 | -1,583.36% |
| Jun 30, 2022 | 97.25% |
| Mar 31, 2022 | -195.52% |
| Dec 31, 2021 | -3,779.80% |
| Sep 30, 2021 | 89.96% |
| Jun 30, 2021 | -670.72% |